Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for tags : Disease save search
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.16 0.08% 0.53% 1.2M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
entyvio fda disease active for therapy
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | News | $42.14 1.3% 1.33% 1.3M
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
Published: 2024-04-16 (Crawled : 05:00) - globenewswire.com
ARGX | $358.41 -2.13% -2.11% 220K
|
Health Technology
|
| O: -5.0%
H: 4.19%
C: 2.86%
disease vyvgart for
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
Published: 2024-04-15 (Crawled : 21:00) - globenewswire.com
ZVRA | $4.5 -3.02% -2.88% 260K
|
n/a
|
| O: 1.15%
H: 1.03%
C: -1.45%
disease treatment for meeting therapeutics
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
LGVN | News P 0 d | $2.01 -3.83% -4.24% 970K
|
|
| O: 41.42%
H: 42.68%
C: 22.59%
conference disease association alzheimer’s presentation international research for trial
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
OABI | $4.59 -3.98% -3.91% 1.1M
|
|
| O: -1.58%
H: 1.77%
C: -0.4%
drug liver disease antibody for
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
LLY | $745.95 -0.64% -0.13% 17K
|
Health Technology
|
| O: 1.06%
H: 0.47%
C: -0.03%
fda device disease test granted blood designation for alzheimer's roche
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
SILO | $1.97 0.51% 1.02% 6.7K
|
Finance and Insurance
|
| O: 1.87%
H: 4.59%
C: -3.67%
pharma disease alzheimer’s acquire spc-14
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: 0.73%
H: 2.49%
C: 0.11%
abrysvo disease positive risk for rsv results study
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
ABOS | $3.16 -8.93% -9.12% 640K
|
Professional, Scientific, and T...
|
| O: 4.19%
H: 2.01%
C: -3.52%
disease alzheimer’s treatment pharmaceuticals
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
Published: 2024-04-01 (Crawled : 22:00) - globenewswire.com
OCGN | News A | $1.32 -8.33% -9.51% 7.7M
|
Health Technology
|
| O: -10.0%
H: 0.69%
C: -4.17%
ocu410 disease review positive study
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VRTX | News | $393.48 0.1% 0.1% 780K
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
vx-147 disease kidney treatment trial
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
SLDB | $9.26 -7.31% -8.12% 140K
|
Health Technology
|
| O: -9.02%
H: 0.0%
C: -7.65%
sgt-003 fda rare candidate disease designation duchenne therapy
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Published: 2024-03-31 (Crawled : 00:00) - prnewswire.com
BIIB | $190.52 -0.85% -0.84% 1.3M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
leqembi fda disease license treatment alzheimer's application submission
Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients
Published: 2024-03-28 (Crawled : 07:00) - prnewswire.com
TVTX | $5.8 -3.17% -3.19% 970K
|
Health Technology
|
| O: 0.91%
H: 3.1%
C: -0.39%
AKBA | $1.39 -0.72% 2.4M
|
Health Technology
|
| O: 10.27%
H: 0.4%
C: -25.91%
vafseo fda disease kidney anemia approved treatment
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
Published: 2024-03-28 (Crawled : 01:00) - prnewswire.com
AKBA | $1.39 -0.72% 2.4M
|
Health Technology
|
| O: 10.27%
H: 0.4%
C: -25.91%
vafseo fda disease kidney anemia approval treatment dialysis
Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease
Published: 2024-03-26 (Crawled : 19:00) - biospace.com/
DNLI | $16.6 -1.31% -1.33% 830K
|
Health Technology
|
| O: 1.33%
H: 0.25%
C: -1.27%
disease parkinson's health technology biomarkers
The9 Signed a Definitive Share Purchase Agreement to Invest in GenAI LLM Digital Precision Medicine Platform for Brain Disease WM Therapeutic
Published: 2024-03-26 (Crawled : 12:00) - prnewswire.com
JNJ | News | $145.74 0.67% -0.18% 7M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
NCTY | $6.0 4.35% -5.07% 22K
|
Technology Services
|
| O: 6.25%
H: 0.0%
C: -4.2%
precision disease agreement platform
Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
DGX | $125.91 -0.84% 0.0% 870K
|
Health Services
|
| O: 0.26%
H: 0.1%
C: -0.58%
disease test blood alzheimer's imaging study
United States Food & Drug Administration Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease
Published: 2024-03-26 (Crawled : 07:00) - biospace.com/
MESO | $5.11 2.0% 2.53% 260K
|
Health Technology
|
| O: 23.18%
H: 0.0%
C: 0.0%
drug disease children food trial submission
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
ZCMD | $1.45 5.84% 49.63% 15M
|
Commercial Services
AULT | $0.2421 -7.7% 45.23% 16M
|
Manufacturing
TPET | $0.3279 -3.56% 28.48% 33M
|
n/a
TIRX | $0.8 65.02% 25.95% 410K
|
VTNR 4 | $1.31 33.78% 25.82% 220K
|
Industrial Services
GDHG | $0.263 21.76% 25.34% 1.3M
|
HOLO | $2.95 31.7% 22.49% 37M
|
MTNB | $0.19 -1.04% 14.58% 950K
|
Health Technology
THCH | News | $1.28 23.08% 13.33% 79K
|
n/a
UMAC | $1.55 0.65% 12.9% 0
|
Your saved searches
Save your searches and get alerts when important news are released.